3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
13
Phase 1/2
7
Phase 1
7
Phase 3
2
Phase EARLY_PHASE1
1
Phase 2/3
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma
35
Small Cell Lung Carcinoma
34
Leukemia
34
Lung Neoplasms
25
Leukemia, Myeloid, Acute
25
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Lymphoma, Large B-Cell, Diffuse
19
Neuroblastoma
15
Lymphoma, Non-Hodgkin
15
Carcinoma, Non-Small-Cell Lung
14
Leukemia, Erythroblastic, Acute
13
Hodgkin Disease
13
Leukemia, Myelomonocytic, Acute
12
Leukemia, Monocytic, Acute
12
Leukemia, Megakaryoblastic, Acute
12
Sarcoma
11
Lymphoma, Follicular
10
Burkitt Lymphoma
10
Lymphoma, Large-Cell, Immunoblastic
9
Testicular Neoplasms
7
Teratoma
7
Myelodysplastic Syndromes
7
Congenital Abnormalities
7
Multiple Myeloma
6
Endodermal Sinus Tumor
6
Anemia, Refractory, with Excess of Blasts
6
Testicular Germ Cell Tumor
5
Ovarian Neoplasms
5
Neuroectodermal Tumors, Primitive, Peripheral
5
Central Nervous System Neoplasms
5
Interventions
Rituximab
14
pirtobrutinib
6
ibrutinib
4
Vincristine
4
Doxorubicin
4
Prednisone
3
Cytarabine
3
Cyclophosphamide
3
zanubrutinib
2
acalabrutinib
2
Methotrexate
2
Etoposide
2
Bendamustine Hydrochloride
2
venetoclax
1
tositumomab I-131
1
idelalisib
1
ibritumomab tiuxetan
1
etoposide phosphate
1
entecavir
1
cirmtuzumab
1
axicabtagene ciloleucel
1
VAP-cyclo protocol
1
Tenofovir
1
Radiotherapy
1
Melphalan
1
Ifosfamide
1
Gemcitabine
1
Everolimus
1
Drug Therapy
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, B-Cell
×
Etoposide
×
Clear all
NCT06230224
2026-05-11
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3
Active not recruiting
216 enrolled
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts